TITLE

Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis

AUTHOR(S)
Kühbacher, I.; Ott, S. J.; Helwig, U.; Mimura, T.; Rizzello, F.; Kleessen, B.; Gionchetti, P.; Blaut, M.; Campieri, M.; Fölsch, U. R.; Kamm, M. A.; Schreiber, S.
PUB. DATE
June 2006
SOURCE
Gut;Jun2006, Vol. 55 Issue 6, p833
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The intestinal microbiota plays a critical role in the pathophysiology of pouchitis, a major complication after ileal pouch anal anastomosis in patients with ulcerative colitis. Recently, controlled trials have demonstrated that probiotics are effective in maintenance of remission in pouchitis patients. However, the mechanism by which therapy with probiotics works remains elusive. This study explores the role of the bacterial and fungal flora in a controlled trial for maintenance of remission in pouchitis patients with the probiotic VSL#3 compound. Methods: The mucosa associated pouch microbiota was investigated before and after therapy with VSL#3 by analysis of endoscopic biopsies using ribosomal DNA/RNA based community fingerprint analysis, clone libraries, real time polymerase chain reaction (PCR), and fluorescence in situ hybridisation. Patients were recruited from a placebo controlled remission maintenance trial with VSL#3. Results: Patients who developed pouchitis while treated with placebo had low bacterial and high fungal diversity. Bacterial diversity was increased and fungal diversity was reduced in patients in remission maintained with VSL#3 (p = 0.001). Real time PCR experiments demonstrated that VSL#3 increased the total number of bacterial cells (p=0.002) and modified the spectrum of bacteria towards anaerobic species. Taxa specific clone libraries for Lactobacilli and Bifidobacteria showed that the richness and spectrum of these bacteria were altered under probiotic therapy. Conclusions: Probiotic therapy with VSL#3 increases the total number of intestinal bacterial cells as well as the richness and diversity of the bacterial microbiota, especially the anaerobic flora. The diversity of the fungal flora is repressed. Restoration of the integrity of a "protective" intestinal mucosa related microbiota could therefore be a potential mechanism of probiotic bacteria in inflammatory barrier diseases of the lower gastrointestinal tract.
ACCESSION #
22212750

 

Related Articles

  • CX3CR1 regulates intestinal macrophage homeostasis, bacterial translocation, and colitogenic Th17 responses in mice. Medina-Contreras, Oscar; Geem, Duke; Laur, Oskar; Williams, Ifor R.; Lira, Sergio A.; Nusrat, Asma; Parkos, Charles A.; Denning, Timothy L. // Journal of Clinical Investigation;Dec2011, Vol. 121 Issue 12, p4787 

    The two most common forms of inflammatory bowel disease (IBD), Crohn's disease and ulcerative colitis, affect approximately 1 million people in the United States. Uncontrolled APC reactivity toward commensal bacteria is implicated in the pathogenesis of the disease. A number of functionally...

  • NASAL INVOLVEMENT IN INFLAMMATORY BOWEL DISEASE. Cilursu, Ana M. // American Journal of Gastroenterology;Jul1994, Vol. 89 Issue 7, p1111 

    Describes a case wherein a patient developed nasal ulcerations as part of a constellation of extra-intestinal manifestations of inflammatory bowel disease, including oral/pharyngeal ulcerations and oligoarthritis. Occurrence of nasal ulcerations; Initial treatment for the patient; Importance of...

  • Acute Tubular Injury Associated with Mesalazine Therapy in an Adolescent Girl with Inflammatory Bowel Disease. Nuray Uslu; Hulya Demir; Inci Saltik-Temizel; Rezan Topaloğlu; Figen Gürakan; Aysel Yüce // Digestive Diseases & Sciences;Nov2007, Vol. 52 Issue 11, p2926 

    Abstract  Mesalazine is a first-line drug in pediatric inflammatory bowel disease, and is effective as primary treatment and maintenance therapy. It’s usually well tolerated, but various side effects have been described. A 15-year-old female with ulcerative colitis...

  • Research brief: Mycobacterium link to Crohn's.  // GP: General Practitioner;9/24/2004, p10 

    The article presents information about ulcerative colitis. The U.S. researchers examined 28 people with Crohn's disease, nine with ulcerative colitis and 15 without bowel disease for presence of Mycobacterium avium subspecies paratuberculosis (MAP). MAP was cultured from the blood of half the...

  • Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease. Doering, J.; Begue, B.; Lentze, M. J.; Rieux-Laucat, F.; Goulet, O.; Schmitz, J.; Cerf-Bensussan, N.; Ruemmele, F. M. // Gut;Dec2004, Vol. 53 Issue 12, p1632 

    Background: lamina propria T lymphocytes (LPL) of the intestinal mucosa are chronically activated in Crohn's disease (CD). Defective apoptosis of activated LPL was proposed as a key pathogenic mechanism. In fact, increased expression of antiapoptotic molecules was observed in CD LPL. In the...

  • Treatment of Ulcerative Colitis with a Humanized Antibody to the α4β7 Integrin. Feagan, Brian G.; Greenberg, Gordon R.; Wild, Gary; Fedorak, Richard N.; Paré, Pierre; McDonald, John W.D.; Dubé, Rejean; Cohen, Albert; Steinhart, A. Hillary; Landau, Steven; Aguzzi, Rasha A.; Fox, Irving H.; Vandervoort, Margaret K. // New England Journal of Medicine;6/16/2005, Vol. 352 Issue 24, p2499 

    Background: Selective blockade of interactions between leukocytes and vascular endothelium in the gut is a promising strategy for the treatment of inflammatory bowel diseases. Methods: We conducted a multicenter, double-blind, placebo-controlled trial of MLN02, a humanized antibody to the...

  • Chloroquine for Mild to Moderately Active Ulcerative Colitis: Comparison with Sulfasalazine. Goenka, M. K.; Kochhar, R.; Tandia, B.; Mehta, S. K. // American Journal of Gastroenterology;May1996, Vol. 91 Issue 5, p917 

    Chloroquine and hydroxychloroquine have been used successfully in a number of immunological diseases because of their immunomodulatory effect. Preliminary studies have shown them to be effective in the treatment of idiopathic ulcerative colitis. We assessed the efficacy of oral chloroquine in...

  • If at First You Don't Succeed .. Try Again? Kane, Sunanda; Johnson, David // American Journal of Gastroenterology;Jul2001, Vol. 96 Issue 7, p2260 

    The histories of patients prescribed 6-mercaptopurine over a 2-yr time were examined. Those patients who had initially failed azathioprine therapy before initiating 6-mercaptopurine were included in the study. Clinical data were collected from medical records as well as from patient interviews....

  • Determination of Prothrombin Activation Fragments in Young Patients with Inflammatory Bowel Disease. Smith, C. J.; Haire, W. D.; Kaufman, S. S.; Mack, D. R. // American Journal of Gastroenterology;Jun1996, Vol. 91 Issue 6, p1221 

    Objective: To assess coagulation cascade activation as a potential index of thromboembolic risk in inflammatory bowel disease (IBD). Study design: Fifty plasma samples were obtained during consecutive outpatient encounters with 29 patients (male:female = 20:9) with either Crohn's disease (CD) (n...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics